Novel way to increase targeting specificity to a human gliblastoma- associated receptor for interleukin 13

International Journal of Cancer

Volumn 76, Issue 4, 1998, Pages 547-551

  Debinski, Waldemar ^a,c   Gibo, Denise M ^a   Puri, Raj K ^b  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIN; INTERLEUKIN 13; INTERLEUKIN 13 RECEPTOR; INTERLEUKIN 4; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; RECEPTOR BLOCKING AGENT; RESTRICTION ENDONUCLEASE;

ARTICLE; CELL SPECIFICITY; CONTROLLED STUDY; CYTOTOXICITY; GENE EXPRESSION; GENE TARGETING; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ADENOCARCINOMA; ADP RIBOSE TRANSFERASES; BACTERIAL TOXINS; BRAIN NEOPLASMS; ENDOTHELIUM; EXOTOXINS; GLIOBLASTOMA; HUMANS; INTERLEUKIN-13; PSEUDOMONAS AERUGINOSA; RECEPTORS, INTERLEUKIN; TUMOR CELLS, CULTURED; VIRULENCE FACTORS;

EID: 0031969574     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19980518)76:4<547::AID-IJC17>3.0.CO;2-4     Document Type: Article

References (25)

1. ATKINS, M.B., VACHINO, G., TILG, HJ., KARP, D.D., ROBERT, N.J., KAPPLER, K. and MIER, J.W., Phase I evaluation of thrice-daily intravenous bolus interleukin-4 in patients with refractory malignancy. J. clin. Oncol., 10, 1802-1809 (1992).
2. CAPUT, D., LAURENT, P., KAGHAD, M., LELIAS, J.-M., LEFORT, S., VITA, N. and FERRARA, P., Cloning and characterization of a specific interleukin (IL)-13 binding protein structurally related to the IL-5 receptor a chain. J. biol. Chem., 271, 16921-16926 (1996).
3. DEBINSKI, W., KARLSSON, B., LINDHOLM, L., SIEGALL, C.B., WILLINGHAM, M.C., FITZGERALD, D. and PASTAN, I., Monoclonal antibody C242Pseudomonas exotoxin A: a specific and potent immunotoxin with antitumor activity on a human colon cancer xenograft in nude mice. J. clin. Invest., 90, 405-411 (1992).
4. DEBINSKI, W., MINER. R., OBIRI, N.I. and PURI, R.K., Receptor for IL13 does not interact with IL4 but receptor for IL4 interacts with IL13 on human glioma cells. J. biol. Chem., 271, 22428-22433 (1996).
5. DEBINSKI, W., OBIRI, N.I., PASTAN, I. and PURI, R.K., A novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for interleukin 13 and interleukin 4. J. biol. Chem., 270, 16775-16780 (1995b).
6. DEBINSKI, W., OBIRI, N.I., POWERS. S.K., PASTAN, I. and PURI, R.K., Human glioma cells overexpress receptor for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin. Clin. Cancer Res., 1, 1253-1258 (1995a).
7. DEBINSKI, W., PURI, R.K., KREITMAN, R.J. and PASTAN, I., A wide range of human cancers express interleukin 4 (IL4) receptors that can be targeted with chimeric toxin composed of IL4 and Pseudomonas exotoxin. J. biol. Chem., 268, 14065-14070 (1993).
8. DEBINSKI, W., PURI, R.K. and PASTAN, I., Interleukin-4 receptors expressed on tumor cells may serve as a target for anticancer therapy using chimeric Pseudomonas exotoxin. Int. J. Cancer, 58, 744-748 (1994).
9. c into the receptor complex. Eur. J. Biochem., 228, 305-310 (1995).
10. FRANKEL, A.E., FITZGERALD, D., SIEGALL, C. and PRESS, O.W., Advances in immunotoxin biology and therapy: a summary of the Fourth International Symposium on Immunotoxins. Cancer Res., 56, 926-932 (1996).
11. HUSAIN, S.R., OBIRI, N.I., GILL, P., ZHENG, T., PASTAN, I., DEBINSKI, W. and PURI, R.K., Receptor for interleukin 13 on AIDS-associated Kaposi's sarcoma cells serves as a new target for a potent Pseudomonas exotoxinbased chimeric toxin protein. Clin. Cancer Res., 3, 151-156 (1997).
12. INOCENCIO, N.M., MOEHRING, J.M and MOEHRING, T.J., Furin activates Pseudomonas exotoxin A by specific cleavage in vivo and in vitro. J. biol. Chem., 269, 31831-31835 (1994).
13. KRUSE, N., TONY, H.P. and SEBALD, W., Conversion of human interleukin-4 into a high affinity antagonist by a single amino acid replacement. EMBO J., 11, 3237-3244 (1992).
14. MOSCATELLO, D.K., HOLGADO-MADRUGA, M., GODWIN, A.K., RAMIREZ, G., GUNN, G., ZOLTICK, P.W., BIEGEL, J.A., HAYES, R.L. and WONG, A.L., Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res., 55, 5536-5539 (1995).
15. OBIRI, N.I., DEBINSKI, W., LEONARD, W.J. and PURI, R.K., Receptor for interleukin 13: interaction with interleukin 4 by a mechanism that does not involve the common γ subunit of interleukins 2, 4, 7 and 15 receptor. J. biol. Chem., 270, 8797-8804 (1995).
16. OBIRI, N.I., HUSAIN, S.R., DEBINSKI, W. and PURI, R.K., Interleukin 13 inhibits growth of human renal cell carcinoma cells independently of the p140 interleukin 4 receptor chain. Clin. Cancer Res., 2, 1743-1749 (1996).
17. OBIRI, N.I., LELAND, P., MURATA, T., DEBINSKI, W. and PURI, R.K., The IL-13 receptor structure differs on various cell types and may share more than one component with IL-4 receptor. J. Immunol., 158, 756-764 (1997).
18. PASTAN, I., CHAUDHARY, V.K. and FITZGERALD, D., Recombinant toxins as novel therapeutic agents. Ann. Rev. Biochem., 61, 331-354 (1992).
19. PURI, R.K., LELAND, P., OBTRI, N.I., HUSAIN, S.R., KREITMAN, R.J., HAAS, G.P., PASTAN, I. and DEBINSKI, W., Targeting of interleukin-13 receptor on human renal cell carcinoma cells by a recombinant chimeric protein composed of interleukin 13 and a truncated form of Pseudomonas exotoxin A (PE38QQR). Blood. 87, 4333-4339 (1996).
20. SCHNYDER, B., LUGLI, S., FENG, N., EITER, H., LUTZ, R.A., RYFFEL, B., SUGAMURA, K., WUNDERLI-ALLHNSPACH, H. and MOSER, R., Interleukin-4 (IL-4) and IL-13 bind to a shared heterodimeric complex on endothelial cells mediating vascular cell adhesion molecule-1 induction in the absence of the common γ chain. Blood. 87, 4286-4295 (1996).
21. TONY, H.-P. SHEN, B.-J., REUSCH, P. and SEBALD, W., Design of human interleukin-4 antagonists inhibiting interleukin-4-dependent and interleukin13-dependent responses in T-cells and B-cells with high efficiency. Europ. J. Biochem., 225, 659-665 (1994).
22. WIKSTRAND, C.J. and 13 OTHERS. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res., 55, 3140-3148 (1995).
23. YOULE, R.J., Immunotoxins for central nervous system malignancy. Semin. Cancer Biol. 7, 65-70 (1996).
24. ZURAWSKI, S.M., CHOMARAT, P., DJOSSOU, O., BIDAUD, C., MCKENZIE, A.N.J., MIOSSEC, P., BANCHEREAU, J. and ZURAWSKI, G., The primary binding subunit of the human interleukin-4 receptor is also a component of the interleukin-13 receptor. J. biol. Chem., 270, 13869-13878 (1995).
25. ZURAWSKI, S.M., VEGA, F., JR., HUYGHE, B. and ZURAWSKI, G., Receptors for interleukin-13 and interleukin-4 are complex and share a novel component that functions in signal transduction. EMBO J., 12, 2663-2670 (1993).